{"url_path":"/sec/mtva/8-k/2026-07-09/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-082116-index.html","accession_number":"0001104659-26-082116","cik":"0001638287","ticker":"MTVA","issuer_name":"MetaVia Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1638287/0001104659-26-082116-index.html","primary_entity_key":"0001638287","primary_entity_name":"MetaVia Inc."},"word_count":168,"has_tables":true,"body_markdown":"**Item 8.01****Other Events.**\n\n \n\nOn July 9, 2026, the Company provided an\nupdate on its ongoing Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity, reporting that all enrolled\nactive patients in the trial have successfully completed dose titration and are now receiving their highest target doses of 48 mg and\n64 mg in both study cohorts. The Company is still planning to release the data readout for Part 3 of its Phase 1 clinical trial evaluating\nDA-1726 in the fourth quarter of 2026.\n\n \n\n*Forward-Looking Statements*\n\n \n\nThis Report, including Exhibit 99.1 attached\nhereto, contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements\nare based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are\nsubject to the limitations listed in Exhibit 99.1 and in the other reports that the Company has filed with the Securities and Exchange\nCommission, including that actual events or results may differ materially from those in the forward-looking statements."}